• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cannara Biotech Inc (OP: LOVFF )

    0.5388 UNCHANGED
    Streaming Delayed Price Updated: 2:07 PM EDT, Aug 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.5388
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.5388
    Today's Range 0.5388 - 0.5388
    52wk Range 0.4010 - 0.7850
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cannara Biotech Reports 6% YoY Drop In Q3 Gross Profit, 22% Revenue Increase As It Enhances Sales Force And Infrastructure
    Vertically integrated cannabis company Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0) announced on Tuesday its fiscal third quarter 2024 financial and operating results for the three and... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Cannara Biotech Reports Q3 2024 Financial Results
    From Cannara Biotech (Québec) Inc.
    Via GlobeNewswire

    Performance

    YTD
    -13.74%
    -13.74%
    1 Month
    +22.90%
    +22.90%
    3 Month
    -14.48%
    -14.48%
    6 Month
    -16.65%
    -16.65%
    1 Year
    -30.92%
    -30.92%

    More News

    Read More
    Cannabis Slowdown In Canada: Analyst Spotlights What Still Sells And Where The Money Is Going
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    This Cannabis Producer Reports It Is Able to Deliver Some Of The Highest Quality Product To Market At Some Of The Most Competitive Prices
    Via News Direct
    Topics Cannabis
    Exposures Cannabis
    The 7 Most Undervalued Cannabis Stocks to Buy in December
    Via InvestorPlace
    Topics Cannabis
    Exposures Cannabis
    This Cannabis Producer Reports It Is Able to Deliver Some Of The Highest Quality Product To Market At Some Of The Most Competitive Prices
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    7 Smoking-Hot 420 Stocks to Buy in 2023
    Via InvestorPlace
    Topics Cannabis
    Exposures Cannabis
    Cannabis Stock Movers For August 10, 2023
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Cannara Biotech Q3 FY23 Net Revenue Grows 57% YoY, What About Adjusted EBITDA?
    Via Benzinga
    Cannabis Stock Gainers And Losers From July 25, 2023
    Via Benzinga
    Cannabis Stock Gainers And Losers From August 4, 2023
    Via Benzinga
    Cannara Biotech Secures An Additional $10M In Non-Dilutive Capital With Its Lead Credit Provider, BMO Commercial Banking
    Via Benzinga
    Cannara Biotech Q2 FY23 Revenue Grows 76% YoY To $9.6M, Here Are The Details
    Via Benzinga
    Marijuana Stock Movers For August 1, 2023
    Via Benzinga
    Olymbec Investments Increases Its Ownership In Cannara Biotech
    Via Benzinga
    Cannara Biotech Q1 Revenue Grows 57% YoY To $7.7M, What About Adjusted EBITDA?
    Via Benzinga
    Cannabis Stock Movers For July 27, 2023
    Via Benzinga
    Cannara Biotech Q4 Revenue Grows 84% YoY To $8.9M
    Via Benzinga
    Cannara Biotech Enters Into The British Columbia Cannabis Market And Launches New Products
    Via Benzinga
    Cannara Biotech Signs An Exclusive Brand Partnership With Exotic Genetix In Canada
    Via Benzinga
    Cannara Biotech Revenue Grows 41% YoY, Here Are The Details
    Via Benzinga
    Cannara Biotech Closes $50 Million Credit Facility Led By BMO Commercial Banking
    Via Benzinga
    Cannara Biotech Revenues Grew 229% To $7.4M In Q2 2022 YoY
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.